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Biofilms play a major role in delaying chronic wounds from healing. A wound
infiltrated with biofilm, or “critically colonised” wound, may become clinically
infected if the number of microbes exceeds a critical level. Chronic wound bio-
films represent a significant treatment challenge by demonstrating recalcitrance
towards antimicrobial agents. However, a “window of opportunity” may exist
after wound debridement when biofilms are more susceptible to topical antisep-
tics. Here, we discuss the role of antiseptics in the management of chronic
wounds and biofilm, focusing on povidone-iodine (PVP-I) in comparison with
two commonly used antiseptics: polyhexanide (PHMB) and silver. This article is
based on the literature reviewed during a focus group meeting on antiseptics in
wound care and biofilm management, and on a PubMed search conducted in
March 2020. Compared with PHMB and silver, PVP-I has a broader spectrum of
antimicrobial activity, potent antibiofilm efficacy, no acquired bacterial resistance
or cross-resistance, low cytotoxicity, good tolerability, and an ability to promote
wound healing. PVP-I represents a viable therapeutic option in wound care and
biofilm management, with the potential to treat biofilm-infiltrated, critically
colonised wounds. We propose a practical algorithm to guide the management of
chronic, non-healing wounds due to critical colonisation or biofilm, using PVP-I.
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1 | INTRODUCTION
Wound healing is a complicated and tightly regulated pro-
cess that is essential to restore the normal barrier function
of the skin, thereby preventing further damage or infec-
tion.1,2 The normal wound healing process involves
sequential but overlapping phases, including inflamma-
tion, proliferation, and remodelling.1 These phases are
mediated by a range of cell types including fibroblasts,
keratinocytes, endothelial cells, and macrophages, the
activity of which is carefully coordinated by a range of
growth factors, cytokines, and chemokines.3 However,
when a wound fails to progress through the normal suc-
cessive phases of wound healing in an orderly and timely
manner, a chronic wound may result.1,4 Chronic wounds,
comprising vascular leg ulcers (eg, venous and arterial
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ulcers), diabetic foot ulcers, and pressure ulcers, represent
a significant burden to the individual and to the
healthcare system.5,6 There are many factors that may be
responsible for the delay and/or failure of a chronic
wound to heal, including the patient's age, the nutritional
status (eg, obesity) of the patient, how oxygenated the
wound is, and the presence of either an underlying
chronic disease (eg, diabetes) or an immunocompromised
condition (eg, cancer).7,8 Certain therapies may also hin-
der wound healing, including chemotherapeutic agents,
radiation therapy and long-term use of corticosteroids,
and non-steroidal anti-inflammatory drugs.9,10
Perhaps the most important factor that can affect the
healing of a chronic wound, and subsequently increase
the likelihood the wound may become infected, is the
presence of a biofilm.11-14 Biofilms are generally poly-
microbial communities, attached either to each other or
to a surface that become encased within an extracellular
polymeric substance (EPS).11,15,16 Most biofilms located
within chronic wounds are composed of 10% to 20%
microorganisms and 80% to 90% EPS.11 Biofilms cause
chronic wounds to become locked in an inflammatory
state,17,18 and they are thought to be the root cause of
approximately 80% of all infections in humans,11 and
most medical device-related infections.19 A recent system-
atic review and meta-analysis has proposed that the prev-
alence of biofilms in chronic wounds is 78.2%, although a
more conservative estimate suggests that the figure may
be 60%.13,20 Biofilms in chronic wounds are difficult to
visualise macroscopically, and whether located on the sur-
face of a wound or deeper in the wound bed, the identifi-
cation and diagnosis of biofilms in chronic wounds can be
challenging.21 Although tissue biopsies are regarded as
one of the most reliable methods to detect biofilms in
wounds, the procedure can be invasive, painful, and
expensive, and usually requires a specifically trained prac-
titioner to be performed.22-24 Furthermore, the distribu-
tion of biofilms within chronic wounds is not thought to
be uniform,25 so a single biopsy sample taken from just
one small area of a wound may not be enough to confirm
the presence of biofilm within the wound as a whole. An
algorithm to help identify (and treat) suspected biofilms
has been developed, which is intended to guide the clini-
cal management of chronic wounds.11 In addition, recent
consensus guidelines have been proposed to help clini-
cians recognise the signs and symptoms of biofilms in
chronic, non-healing wounds, thereby optimising patient
care.21 Nevertheless, there are currently no “gold stan-
dard” diagnostic tests to enable clinicians to confirm the
presence of biofilms in chronic wounds.11,18,21,26
The “wound infection continuum” conceptualises the
relationship between bacteria, wound, and host,12 and a
key phase of this continuum is “critical colonisation”,
which marks the proliferation of microbes within the
wound and the development of biofilm.8 Agreement is yet
to be reached on how best to define the term critical colo-
nisation, but Cutting (2003) suggested it refers to a wound
that has become compromised by microbes, resulting in
delayed healing without causing the classic signs and
symptoms traditionally associated with clinical infec-
tion.27 A critically colonised—or more generally biofilm
infiltrated—wound has the potential to deteriorate to clin-
ical infection once microbes reach a critical level (105
colony-forming units per gram tissue); should the num-
bers of bacteria increase above this level, the likelihood of
infection increases as the host's immune system may no
longer be able to control the proliferating microbes.8,28 In
contrast, an infected wound marks the presence of multi-
plying microbes, which have already overwhelmed the
host's immune system, leading to the traditional clinical
signs of inflammation, including redness, swelling,
warmth, pain, and potentially fever.28-30 Alternative terms
do exist in the literature to describe a wound that is criti-
cally colonised, including “sub-clinically infected”, but at
present there appears to be no consensus on how best to
describe this stage in the wound infection contin-
uum.8,12,29 White and Cutting (2008) argued that critical
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colonisation is a cause of delayed healing and failure to
acknowledge this important clinical step in the wound
infection continuum could jeopardise the early diagnosis
and treatment of a chronic wound.29 Therefore, if a
biofilm-infiltrated chronic wound can be treated before
advancing beyond critical colonisation, this should not
only improve the status of the wound but also help to
avoid any significant personal and economic burden
should the wound subsequently become infected.29
To date, therapeutic intervention to eradicate biofilms
in chronic wounds has relied principally on the use of
conventional antibiotics and antiseptics.16 However,
chronic wound biofilms can be highly tolerant and resis-
tant to antibiotics and antiseptics.21,31 A wide range of
molecular mechanisms are thought to contribute to the
recalcitrance of biofilms towards antimicrobial agents,
which may subsequently lead to treatment failure.31-35
Debridement also represents a viable treatment strategy
against biofilms, but it is unable to completely remove all
biofilm and so is not recommended for use alone.21 Bio-
films may reform quickly, even after repeated debride-
ment, yet a time-dependent “window of opportunity” is
thought to exist after debridement during which biofilms
are more susceptible to treatment, in particular topical
antiseptics.21,31,36 By delaying biofilm reformation after
debridement, topical antiseptics may reduce the risk of
infection and subsequent need for antibiotics, helping to
minimise the potential for antibiotic resistance to
develop.21 Indeed, recent consensus guidelines recom-
mend topical antiseptics as first-line therapy in the treat-
ment of stalled (chronic) wounds.21
Here, we review the antibiofilm efficacy, safety, and
tolerability of topical antiseptics in chronic wound care
and biofilm management, focusing specifically on
povidone-iodine (PVP-I) in comparison with two com-
monly used antiseptics in wound care, poly-
hexamethylene biguanide/polyhexanide (PHMB), and
silver. We also propose a new practical clinical guide or
algorithm for the treatment of chronic, non-healing
wounds due to critical colonisation or biofilm.
2 | METHODS
This narrative review results from a Focus Group meet-
ing on “antiseptics in wound care and biofilm manage-
ment” held in December 2019. The review is based
primarily on the literature reviewed and recommended
by the authors during the meeting. Additional English
language publications of relevance were identified follow-
ing literature searches conducted in PubMed in March
2020, using various combinations of the key terms: “anti-
microbial”, “biofilm”, “critical colonisation”, “chronic
wound”, “cytotoxicity”, “non-healing wound”, “poly-
hexamethylene biguanide”, “polyhexanide”,
“polihexanide”, “povidone iodine”, “silver”, “silver col-
loid”, “silver compounds”, “silver ion”, “silver
nanoparticles”, “topical antiseptics”, “wound dressing”,
and “wound healing”. The key terms in all searches could
be combined using Boolean operators such as “OR” or
“AND”. No date restrictions in the searches were
employed. Only full-text articles identified from the
searches that were considered directly relevant were
included in this review, and most of these articles were
open access. Reference lists of identified papers were also
hand-searched to identify any further papers of interest.
Reports and academic dissertations were not considered
for inclusion in this review.
3 | RESULTS AND DISCUSSION
3.1 | Antimicrobial spectrum of activity
Differences observed in the antimicrobial spectrum of activ-
ity of PVP-I, PHMB, and silver may stem from the varying
mechanisms of action of each antiseptic. An overview of
the antimicrobial activity and mechanisms of action of
PVP-I, PHMB, and silver is presented in Table 1.37-70
3.1.1 | Povidone-iodine
PVP-I is an iodophor or iodine-releasing agent, consisting
of a complex of iodine and a neutral polymer base (poly-
vinylpyrrolidone), which acts as a reservoir of free active
iodine.37,44,67 PVP-I has a particularly broad antimicro-
bial spectrum of activity that includes Gram-positive and
Gram-negative bacteria (including strains resistant to
antiseptics and antibiotics), fungi, protozoa, viruses, bac-
terial spores, and amoeba.37-43 Studies suggest that PVP-I
exhibits a rapid onset of activity, with antimicrobial effi-
cacy evident after a contact time of 1 minute, although
there were certain study limitations to take into consider-
ation.71,72 Some studies have even demonstrated potent
antimicrobial efficacy of PVP-I in as little as 15 seconds
against certain enveloped viruses (eg, Ebola, Middle East
Respiratory Syndrome coronavirus [MERS-CoV], and
Severe Acute Respiratory Syndrome coronavirus [SARS-
CoV]).73-75 Of significance, a recent in vitro study has
shown that PVP-I also provides rapid and potent activity
against SARS-CoV-2, the virus responsible for the ongo-
ing coronavirus disease 2019 (COVID-19) pandemic.76 In
the study, all topical and oral PVP-I products tested pro-
vided ≥99.99% virucidal activity against SARS-CoV-2
within 30 seconds of contact, suggesting that PVP-I could
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form a valuable part of future COVID-19 infection con-
trol strategies.76 There have been no reports of bacterial
resistance to iodine despite more than 150 years of use,
possibly due to the multiple mechanisms of action
exhibited by free iodine.44,45,48,77 In addition, no evidence
of cross-resistance to antibiotics or other antiseptics has
been observed with PVP-I use in a wide range of Gram-
positive and Gram-negative bacterial species.40,46,47
3.1.2 | Polyhexanide
PHMB is a biguanide, a strong base, which is highly posi-
tively charged at physiological pH.51 Findings from
in vitro studies have demonstrated efficacy of PHMB on
Gram-negative bacteria, Gram-positive bacteria, and
Candida albicans,51 but it is without rapid onset of anti-
microbial activity.72 There have been no reports of bacte-
ria acquiring resistance to PHMB,51-53 possibly a
consequence of its non-specific mechanisms of action.55
Although recent reviews suggest no evidence of cross-
resistance to antibiotics in Gram-positive and Gram-
negative bacteria after low-level exposure to PHMB,46,47
reduced susceptibility of methicillin-resistant Staphylo-
coccus aureus (MRSA) to daptomycin and other cell wall-
targeting antibiotics has been reported.54
3.1.3 | Silver-containing products
Silver-containing products used in wound care (eg, silver
salts, colloidal silver, and more recently, silver
nanoparticles) require the release of positively charged
silver ions in order to exhibit antimicrobial activity.68,78,79
The conversion process of inert metal to active ionised
form is thought to be facilitated by interaction of the sil-
ver contained in wound dressings with aqueous media
(eg, wound exudate).80 The rate of onset of antimicro-
bial efficacy of certain higher silver release formulations
has been demonstrated within 30 minutes of contact
with clinically relevant bacteria.81 Silver has demon-
strated bactericidal activity against Gram-negative and
Gram-positive bacteria, and may also target fungi and
viruses.56-62 Bacterial resistance to silver has been docu-
mented.63-66 Evidence suggests silver resistance is
encoded on plasmids.82 Plasmid-encoded resistance to
silver is of particular concern in the clinical setting as
plasmid transfer between bacteria within polymicrobial-
infected chronic wounds may confer silver resistance
across multiple bacterial species.83 Furthermore,
plasmid-mediated metallic salt resistance has been
shown to be associated with coresistance to antibi-
otics.84 No cross-resistance to antibiotics has been
reported to date.49
TABLE 1 Antimicrobial activity and mechanisms of action for povidone-iodine, polyhexanide, and silver
Characteristic Povidone-iodine Polyhexanide Silver
Spectrum of
activity
Broad spectrum of activity against
Gram-positive and Gram-negative
bacteria, fungi, protozoa, viruses,
bacterial spores, and amoeba37-43
Antimicrobial efficacy on Gram-
negative bacteria, Gram-positive
bacteria, and Candida albicans51
Bactericidal activity against Gram-
negative and Gram-positive
bacteria, fungi, and viruses56-62
Bacterial
resistance
No reports of bacterial resistance44,45 No reports of bacterial resistance51-53 Gram-negative bacteria, including E
coli, P aeruginosa, K pneumoniae,




No reports of cross-resistance to
antibiotics or other
antiseptics40,46,47
Prolonged exposure of MRSA to a
low concentration of PHMB in
vitro associated with reduced
susceptibility, not only to PHMB,




Iodine oxidises fatty acids, amino
acids, and nucleic acids, leading to
destabilisation of cell membranes,
deactivation of cytosolic enzymes,
and disruption of internal
metabolic pathways48-50
Disrupts cell membranes, increasing
membrane permeability via
interaction with acidic, negatively
charged membrane phospholipids,
and inhibits internal metabolic
processes54,55
Ionic form reacts with the thiol
groups in enzymes and proteins,
adversely affecting enzyme
function, cell replication, and
energy generation in a non-
specific manner56,67-69




Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; PHMB, polyhexanide.
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3.2 | Antibiofilm efficacy
3.2.1 | Povidone-iodine
The World Union of World Healing Societies 2016 Posi-
tion Document recognises iodine as a suitable antimicro-
bial agent to manage biofilms,18 and numerous studies
have been conducted to investigate the antibiofilm effi-
cacy of PVP-I. Sub-inhibitory concentrations of PVP-I
(0.17%, 0.35%, and 0.7% w/v) inhibited biofilm develop-
ment by Staphylococcus epidermidis and S aureus, two of
the most prevalent bacterial species found within chronic
wounds.17,85 Using an in vitro model of chronic wound
biofilms, Hill et al (2010) demonstrated that mixed Pseu-
domonas and Staphylococcus biofilms were disrupted by
PVP-I 1% (w/v) solution; in contrast, these mixed bio-
films were unaffected by treatment with ciprofloxacin
and flucloxacillin.86 Furthermore, in the same study,
mature 7-day mixed biofilms were completely destroyed
by PVP-I-containing dressing.86 PVP-I at low doses
(0.25% w/w) completely eradicated established biofilms
of multi-drug resistant S aureus, Klebsiella pneumoniae,
Pseudomonas aeruginosa and C albicans in vitro.87 In a
complex biofilm model, PVP-I 10% solution destroyed
both early (90 minutes) and mature (48 hours) biofilms
formed by Candida auris, an emerging multi-drug resis-
tant yeast.88,89 The antibiofilm efficacy of PVP-I is rapid
in onset in vitro, with total eradication of mature 3-day
biofilms of S aureus and P aeruginosa achieved after only
15 minutes' exposure.90 Using a basally perfused biofilm
model, PVP-I 10% w/v demonstrated greater effectiveness
against a biofilm community consisting of P aeruginosa,
Streptococcus pyogenes, MRSA, and Bacteriodes fragilis
compared with PHMB 0.5% v/v and silver acetate 0.05%
w/v.91 In the study, PVP-I (57%) achieved the largest
reduction in average bacterial count over time vs PHMB
(44%) and silver acetate (27%).91 In a further study,
iodine-containing wound dressings demonstrated greater
antimicrobial efficacy against mature biofilms of P
aeruginosa and S aureus over a 24-hour period compared
with silver-based dressings using an in vitro static diffu-
sion model.92
3.2.2 | Polyhexanide
PHMB is the most used antiseptic to treat critically
colonised and locally infected acute and chronic
wounds.93 Investigations into the antibiofilm efficacy of
PHMB have demonstrated that wound irrigation by
PHMB was effective against MRSA 3- and 6-day biofilms
in a porcine wound model.94 Application of a PHMB-
containing biocellulose dressing to non-healing locally
infected and/or critically colonised wounds provided
good efficacy against existing biofilm in 10 (63%) adult
patients, thereby facilitating wound healing.95 In addi-
tion, comparable efficacy of PHMB to chlorhexidine
(CHG) was demonstrated against P aeruginosa biofilm
grown in routinely used microtitre plates and on silicone
materials in vitro in artificial wound fluid.96 However,
although PHMB was equally as effective as saline solu-
tion in reducing the bacterial load in venous leg ulcers,
neither treatment was able to eliminate biofilm from the
wound tissue.97 Furthermore, conflicting evidence exists
regarding the activity of PHMB against S aureus
biofilms.98,99
3.2.3 | Silver-containing products
Silver has been positioned among first-line options for
the treatment of wound infections and is recommended
for use in biofilm treatment.12,18 Silver sulfadiazine 5 to
10 μg/mL eradicated mature P aeruginosa biofilm
in vitro,100 and colloidal silver 100 and 150 μL almost
completely eliminated S aureus biofilm in vitro 24 hours
after treatment.101 Application of a silver-containing
wound dressing to a 24-hour biofilm composed of either
P aeruginosa, Enterobacter cloacae, S aureus, or a mixed
bacterial community, resulted in total bacterial killing
after 48 hours' exposure.102 Antibiofilm efficacy of silver
ions against S epidermidis is thought to be mediated by
the binding of silver ions to proteins and polysaccharides
within the EPS, leading to breakdown of the EPS and
destabilisation of the overall biofilm structure.103 Silver
nanoparticles are a relatively new addition to the range
of available antimicrobial treatment options.104 Interac-
tion of silver nanoparticles with an aqueous environment
(eg, an exuding wound) promotes oxidation of the
nanoparticles and subsequent release of antimicrobial sil-
ver ions.104 A concentration-dependent effect on P
aeruginosa biofilm development and architecture has
been demonstrated, with complete inhibition of biofilm
growth achieved with a high concentration (18 μg/mL) of
silver nanoparticles.105 Potent antibiofilm efficacy of sil-
ver nanoparticles has been shown against C auris by inhi-
bition of biofilm formation and by the disruption and
distortion of pre-formed biofilms.106 Silver nanoparticles
have demonstrated potent inhibition of biofilm formation
by Escherichia coli, P aeruginosa, and Serratia
proteamaculans.107 A 7-day treatment in vitro study by
Kostenko et al (2010) concluded that the efficacy of silver
against biofilms formed by MRSA, P aeruginosa, and E
coli was determined by the type of silver species and base
materials used in the wound dressings.108
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3.3 | Cytotoxicity and tolerability
A pre-requisite of any wound dressing is to shield the
wound, offering not only a physical protective barrier but
also a first line of defence against antimicrobial invasion
of the wound. Intimate contact between the wound dress-
ing and those cells that are key to the wound healing pro-
cess is inevitable, so it is vital that a wound dressing
demonstrates good cell compatibility.109 Cytotoxic effects
of a wound dressing would reduce the viability, prolifera-
tion, and migration of cells involved in the wound
healing process, and so decrease the healing rate.109 Stud-
ies have shown different levels of cytotoxicity among
PVP-I, PHMB, and silver-containing products
(Table 2).110-129 Cytotoxicity data, in particular data
derived from in vitro studies, must be interpreted with
caution as any cytotoxic effects observed in cultured cell
types can be magnified and may not be truly reflective of
the in vivo or clinical setting.49,130,131
3.3.1 | Povidone-iodine
A cytotoxicity assay conducted in cultured murine fibro-
blasts showed that PVP-I had the lowest cytotoxicity com-
pared with PHMB, silver nitrate, and silver
sulfadiazine.132 A further in vitro cytotoxicity test using
murine fibroblasts demonstrated that PVP-I was less
cytotoxic than a variety of antiseptics, including
PHMB.133 Furthermore, of the antiseptics tested, PVP-I
was unique in provoking a revitalisation of fibroblasts,
which may be pivotal to improved wound healing and
better tissue tolerance with PVP-I.133 In an in vitro study
to investigate the cytotoxic effect of commonly used anti-
septics on human fibroblasts and mesenchymal stromal
cells, PVP-I was the only antiseptic to show remaining
cell viability at the minimal bactericidal concentration
(MBC; 1.32 g/L); in the same study, PHMB was 100%
cytotoxic at the commercially available concentration of
0.04%, which was below the estimated MBC.130 In vitro
TABLE 2 In vitro cytotoxicity of povidone-iodine, polyhexanide and silver-containing products against cell types instrumental to the
wound healing process
Antiseptic Fibroblasts Keratinocytes Endothelial cells
Povidone-iodine Decrease in human fibroblast cell
survival, cell migration, and cell
viability110,111
Decrease in human keratinocyte
cell viability111
Cytotoxic damage in bovine corneal
endothelial cells124




High cytotoxicity in murine
fibroblasts after up to 72 hours of
incubation114
Concentration- and time-dependent
cytotoxicity in human dermal
keratinocytes113
High cytotoxicity in human
keratinocytes after up to 72 hours
of incubation114
Large reduction in human




Cytotoxic effects of silver-based
dressings, silver nitrate, and silver
ions in fibroblasts115-117
Significant change in cell
morphology and decrease in cell
proliferation and collagen
synthesis of human diabetic
fibroblasts (silver-containing
dressings)118
Inhibition of human dermal
fibroblast proliferation with
silver-dependent cell loss (silver
nitrate)119
Time- and concentration-dependent
cytotoxicity in human fibroblasts
(silver nitrate)120
Dose- and time-dependent
cytotoxicity in human periodontal
fibroblasts (silver
nanoparticles)121
Cytotoxic effects of silver-based
dressings, silver nitrate, and silver
ions in keratinocytes115-117
Inhibition of human keratinocyte
growth (nanocrystalline silver
dressing)122
Decrease in human epidermal
keratinocyte viability,
metabolism, and proliferatory
and migratory potential (silver
nanoparticles)123
Formation of reactive oxygen
species and induction of
apoptosis in human umbilical
vein endothelial cells (silver
nanoparticles)126,127
Dose-dependent inhibition of the
proliferation of rat vascular
endothelial cells (silver
nanoparticles)128
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evidence does exist to suggest that PVP-I may also be
cytotoxic towards certain cell types involved in the
wound healing process, including fibroblasts,
keratinocytes, and endothelial cells.110,111,124 However,
Bigliardi et al (2017) commented that PVP-I is well toler-
ated in human studies when used in appropriate concen-
trations, and that pronounced cytotoxicity with PVP-I has
only been observed in certain in vitro studies.134 Indeed,
the densities of dendrocytes and microvessels in chronic
leg ulcers were higher following 6 weeks of PVP-I treat-
ment compared with silver sulfadiazine and CHG, with
no evidence of dendrocytoclasis, which may be consid-
ered a sign of in vivo cytotoxicity.135 In contrast, silver
sulfadiazine and CHG promoted changes in the superfi-
cial microvasculature and induced dendrocytoclasis.135
Overall, PVP-I has a good tolerability profile.49 The prev-
alence of allergic contact dermatitis caused by PVP-I has
been estimated to be approximately 0.4%, with reports of
anaphylaxis exceptionally rare.136
3.3.2 | Polyhexanide
There are reports to suggest that PHMB is cytotoxic
towards cells that are crucial to the wound healing pro-
cess. A range of concentrations of PHMB (0.005%-1.0%
v/v) demonstrated high cytotoxicity against cultured
human keratinocytes and murine fibroblasts after 24 and
72 hours of incubation in vitro.114 In an in vitro cytotox-
icity test using cultured human skin fibroblasts, PHMB
was extremely cytotoxic and appeared to induce complete
cell destruction in the majority of cells.112 When used
in vitro at or below concentrations commonly employed
in human wound care, PHMB (0.01%, 0.04%, and 0.1%)
demonstrated both time- and concentration-dependent
cytotoxicity in cultured human keratinocytes and osteo-
blasts, but only time-dependent cytotoxicity in cultured
fibroblasts.113 Furthermore, exposure of cultured human
endothelial cells to PHMB (0.0006%-0.01%) resulted in a
large reduction in cell number and viability.125 The over-
all tolerability profile of PHMB is good, with report of
contact dermatitis found to be rare.136 However, a recent
case report identified PHMB as an emerging allergen,
which may have induced an anaphylactic reaction.137
3.3.3 | Silver-containing products
Studies have indicated cytotoxic effects of silver-based
dressings and silver nitrate in both cultured fibroblasts
and keratinocytes,115 with silver-based dressings also
shown to cause a significant delay in re-
epithelialisation.116 In addition, silver-based dressings
have been shown to significantly alter the cell morphol-
ogy and decrease cell proliferation and collagen synthesis
of cultured human diabetic fibroblasts in vitro compared
with silver-free dressings, suggesting the use of such
dressings should be closely monitored when treating dia-
betic wounds.118 Although the cytotoxic effects of silver
nanoparticles are thought to be dependent on a number
of factors, including nanoparticle size, shape, concentra-
tion, and aggregation, it remains to be determined if the
cytotoxicity is due to inherent properties of the
nanoparticles themselves or due to the release of ionic sil-
ver following oxidation.138-140 Indeed, ionic silver has
been found to be significantly more cytotoxic in vitro in
human dermal fibroblasts and epidermal keratinocytes
compared with silver nanoparticles.117 Additional in vitro
studies provide further evidence of the cytotoxicity of
silver-based products on fibroblasts, keratinocytes, and
endothelial cells.119-123,126-129 Nevertheless, silver has a
good tolerability profile, and although argyria can result
from the long-term use of silver-based products, any dis-
colouration of the skin is not thought to result in patho-
logical tissue damage or to be in any way a danger to
life.141
3.4 | Wound management
In wound management, it is important to not only con-
sider the antimicrobial efficacy and potential cytotoxicity
of antiseptics, but also to be aware of the way in which
antiseptics may impact the complex cellular and extracel-
lular mechanisms involved in the wound healing pro-
cess.142 One of the many properties an ideal antiseptic
should possess is its ability to facilitate wound healing.49
3.4.1 | Povidone-iodine
PVP-I enhanced wound healing via increased expression
of transforming growth factor-β (TGF-β),
neovascularisation, and re-epithelialisation in a rat acute
skin wound model.143 In vitro evidence suggests that
PVP-I may facilitate wound healing by exerting an anti-
inflammatory effect, scavenging superoxide anions, and
inhibiting the production of reactive oxygen species by
human polymorphonuclear neutrophils.144 Indeed, treat-
ment of venous leg ulcers with PVP-I in combination
with hydrocolloid dressing reduced bacteria-related
inflammation, vasculitis, and phagocytic infiltration of
the ulcers compared with hydrocolloid dressing alone,
resulting in an improved ulcer healing rate.145 In a fur-
ther study, the healing rate of chronic leg ulcers was sig-
nificantly increased by PVP-I vs controls, reducing the
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time to healing by 2 to 9 weeks.135 Recently, a phase IV
prospective study conducted in 106 adult patients showed
that PVP-I foam dressing achieved a shorter
epithelialisation time compared with hydrocellular foam
dressing and conventional petrolatum gauze when used
as a split-thickness skin graft donor site dressing.146 Fur-
ther evidence supports the role of PVP-I in wound
healing when investigated within in vivo human stud-
ies.147,148 Compared with silver-based foam dressings or
control gauze, PVP-I 3% foam dressing was the most
effective dressing in wound healing by promoting
neovascularisation, re-epithelialisation, and collagen
deposition in an in vivo rat wound model.149 Similarly,
PVP-I 10% solution promoted rapid neovascularisation
more effectively than silver nitrate solution in an in vivo
mouse wound model.150
3.4.2 | Polyhexanide
Evidence to date suggests that PHMB may also be benefi-
cial for wound healing. In a recent systematic review, it
was concluded that PHMB may promote the healing of
chronic wounds, reduce the bacterial load, eradicate
MRSA, and lessen wound-related pain.151 A preclinical
study using a mouse wound model demonstrated that
PHMB had more beneficial effects on the microcircula-
tion, angiogenesis, and epithelialisation compared with
chitosan.152 In a further study, PHMB had a more posi-
tive effect upon the blood flow of intact human skin
in vivo than octenidine, suggesting value in the treatment
of critically perfused wounds, such as burns.142 Compari-
son of a PHMB-containing dressing with a silver-based
dressing in patients with critically colonised and locally
infected wounds demonstrated that the PHMB-
containing dressing was significantly faster and more
effective at removing the critical bacterial load over a
28-day period.153 In addition, PHMB has been shown to
protect keratinocytes from bacterial damage by S aureus
and re-establish normal cell proliferation in vitro in a
dose-dependent manner.154 Nevertheless, a recent
in vitro study has suggested that PHMB may exert pro-
inflammatory effects, including increased cytokine secre-
tion and nuclear factor kappa B activation,155 both of
which would hinder the wound healing process.
3.4.3 | Silver-containing products
A Cochrane meta-analysis concluded that there is insuffi-
cient evidence to confirm whether silver-containing prod-
ucts can promote wound healing.156 Furthermore, the
heterogeneous nature of the evidence regarding the
effectiveness of silver-based treatments in wound care is
thought to have hindered the development of treatment
guidelines.157,158 As such, authors of a recent qualitative
literature analysis proposed that silver-containing wound
dressings should be chosen with care if the wound
healing process is not to be impeded.157 Nevertheless,
there is evidence to suggest that silver can have beneficial
effects on the healing of chronic wounds, including those
wounds showing signs of critical colonisation.159,160 For
example, Duan et al demonstrated that a sub-cytotoxic
concentration of silver ions may promote the prolifera-
tion of human skin keratinocytes in vitro.161 Addition-
ally, silver nanoparticles decreased the generation of pro-
inflammatory cytokines by human keratinocytes and
fibroblasts in an in vitro wound healing model.162
3.5 | Algorithm for the treatment of
chronic, non-healing wounds due to
critical colonisation or biofilm
Of the three antiseptics discussed in this review, PVP-I
has particular characteristics that are ideal for the treat-
ment of chronic, non-healing wounds due to critical colo-
nisation and/or biofilm, namely its potent antibiofilm
efficacy, broad spectrum of antimicrobial activity, wound
healing properties, and rapidity of action. Therefore, we
have proposed a new practical clinical guide or algorithm
to remove biofilm and manage critically colonised
wounds, using PVP-I (Figure 1).
When biofilm presence within a chronic wound is
strongly suspected, clinicians should adopt an early inter-
vention plan to remove the biofilm as soon as possible
and reduce the risk of infection.21,23 Wound bed prepara-
tion is vital if successful wound healing is to occur, as
described in the TIMERS (Tissue, Inflammation/infec-
tion, Moisture imbalance, Epithelial edge advancement,
Repair/regeneration, and Social factors) framework to
guide wound care (Figure 2).23,163 According to the new
algorithm proposed here, intensive mechanical washing
or cleansing of the wound with either soap or PVP-I
scrub should help to prepare the wound bed by removing
debris and biofilm from the wound. This should prefera-
bly be performed without causing any additional trauma
to the wound.26 Ideally, cleansing of the wound should
be performed with each change in dressing.12 This is par-
ticularly the case if the likelihood of biofilm is high, but
the unique characteristics of each particular wound bed
should determine the frequency of dressing changes. Fol-
lowing wound cleansing, debridement of the wound can
help to disrupt any remaining biofilm, remove necrotic
tissue, and stimulate wound healing.12,30,163 Debridement
may be achieved using a number of different methods,
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FIGURE 1 A proposed new algorithm for the treatment of chronic, non-healing wounds due to critical colonisation and/or biofilm.
*Secondary dressing is to be used to keep the primary dressing securely in place
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including surgical, mechanical, and chemical tech-
niques.12 The wound can then be disinfected using gauze
impregnated with PVP-I dermic solution. Given the rapid
onset of action of PVP-I, employing a contact time of at
least 1 minute may be sufficient to eradicate the majority
of any microbes remaining in the wound.71,72
Biofilm is not completely removed by debridement
and it may quickly regrow within 24 hours, so debride-
ment alone is not an appropriate treatment strategy.21,36
Regrowth of biofilm must be controlled according to the
status of the wound, in particular the amount of exudate
the wound is producing. A balanced, moist wound
FIGURE 2 TIMERS framework for the management of chronic, non-healing wounds. (Data reproduced with permission of MA
Healthcare Limited, from Atkin et al, 2019; permission conveyed through Copyrigh Clearance Center, Inc.).23 NPWT, negative pressure
wound therapy
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environment is seen as critical for wound healing.23 Not
enough exudate or excessive production of exudate will
hinder the wound healing process.23 Dry wounds are
devoid of exudate, which hinders the activity of tissue-
repairing cells (Figure 3).163 With low and moderate
exuding wounds, the wound bed and surrounding skin
become increasingly wet. The excessive amount of exu-
date produced by a highly exuding wound may result in
maceration of the surrounding skin.30 Therefore, it is
important to manage moisture levels by selecting the cor-
rect dressing.23 Numerous types of dressing are available
to both protect the wound and promote healing
(Table 3).1,164 Choosing the most appropriate option from
the extensive range of dressings available can be a diffi-
cult treatment decision, but it should ultimately be tai-
lored to the characteristics of each wound and to the
patient.23,30 Dressings that manage the exudate and
encourage a balanced wound environment are crucial for
improved patient outcomes.165 The new algorithm pro-
poses that low to moderate exuding wounds can be
treated with PVP-I gel and PVP-I tulle and covered with
a secondary dressing. Highly exuding wounds may be
treated with PVP-I gel applied beneath an absorbent
dressing. Until signs of improvement in the wound bed
surface are evident, dressings should be changed daily
and regularly checked for discolouration, as any change
in colour can indicate reapplication of PVP-I is needed in
order to maintain its clinical efficacy.166 Regular monitor-
ing of the healing status of the wound is required
according to specific criteria, including assessment of the
size and depth of the wound, and the amount and type of
exudate.30 If there is an improvement in wound healing,
FIGURE 3 Different types of exuding wound. Images were kindly provided by the authors P.J.A. and S.M., with permission
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treatment may revert to the standard of care (Figure 2).23
Reassessment of the wound should be made on a weekly
basis and, if necessary, the procedure outlined in the
algorithm can be restarted.
4 | CONCLUSIONS
Recent evidence suggests that the majority of chronic
wounds have biofilms which can hinder wound healing
and result in ineffective treatment, burdening both the
patient and the healthcare system. PVP-I demonstrates
potent efficacy against biofilms formed by a variety of
microbes found to be prevalent within chronic wounds,
including S aureus, S epidermidis, and P aeruginosa.
Given how diverse the microbial community can be
within chronic wounds, the broader spectrum of antimi-
crobial activity of PVP-I should be advantageous vs the
more limited spectrum of antimicrobial activity shown by
PHMB and silver-containing products. PVP-I also fulfils
all of the other requirements of an ideal antiseptic for
chronic wound care, including a lack of acquired bacte-
rial resistance or cross-resistance, wound healing proper-
ties, low cytotoxicity, and good tolerability. Collectively,
these characteristics of PVP-I suggest that it represents a
highly viable therapeutic option in wound care and bio-
film management, with the potential to be particularly
effective during the critically colonised, biofilm-
infiltrated stage of the wound infection continuum. The
proposed new algorithm utilising PVP-I should help to
guide clinicians in the treatment of patients with chronic,
non-healing wounds, which prove particularly unre-
sponsive to treatment.
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